ES2235353T3 - Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular. - Google Patents

Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.

Info

Publication number
ES2235353T3
ES2235353T3 ES98939941T ES98939941T ES2235353T3 ES 2235353 T3 ES2235353 T3 ES 2235353T3 ES 98939941 T ES98939941 T ES 98939941T ES 98939941 T ES98939941 T ES 98939941T ES 2235353 T3 ES2235353 T3 ES 2235353T3
Authority
ES
Spain
Prior art keywords
kinase
cell cycle
pct
protein
thyrasine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98939941T
Other languages
English (en)
Inventor
Mark Robert Barvian
William Alexander Denny
Ellen Myra Dobrusin
James Marino Hamby
Howard Daniel Hollis Showalter
Andrew Mark Thompson
Roy Thomas Winters
Zhipei Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2235353T3 publication Critical patent/ES2235353T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a naftiridinonas representadas por la fórmula (I), que constituyen inhibidores de la proteína tirosina quinasa (PTK) u de quinasas de ciclo celular, y que son útiles para tratar una proliferación celular. Estos compuestos son particularmente útiles en el tratamiento del cáncer, la arterosclerosis, la restenosis y la soriasis.
ES98939941T 1997-08-20 1998-08-13 Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular. Expired - Lifetime ES2235353T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5674697P 1997-08-20 1997-08-20
US56746P 1997-08-20

Publications (1)

Publication Number Publication Date
ES2235353T3 true ES2235353T3 (es) 2005-07-01

Family

ID=22006345

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98939941T Expired - Lifetime ES2235353T3 (es) 1997-08-20 1998-08-13 Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.

Country Status (13)

Country Link
US (1) US6150359A (es)
EP (1) EP1003745B1 (es)
JP (1) JP4965021B2 (es)
KR (1) KR20010023089A (es)
AT (1) ATE286053T1 (es)
AU (1) AU742999B2 (es)
BR (1) BR9811956B1 (es)
CA (1) CA2291222C (es)
DE (1) DE69828408T2 (es)
ES (1) ES2235353T3 (es)
NZ (1) NZ502704A (es)
WO (1) WO1999009030A1 (es)
ZA (1) ZA987491B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911590A (pt) * 1998-05-26 2001-02-13 Warner Lambert Co Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ATE320255T1 (de) 2001-01-19 2006-04-15 Smithkline Beecham Corp Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2002068419A1 (fr) * 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
ATE374201T1 (de) * 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
JP4758349B2 (ja) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007033232A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica, N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
WO2008077064A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Biomarker identifying the reactivation of stat3 after src inhibition
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
CN102083828B (zh) 2008-02-22 2013-11-13 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
CN101684119B (zh) * 2008-09-27 2012-11-28 中国科学院上海药物研究所 5,8-二取代-1,6-二氮杂萘-7-羰酰胺类化合物及其制备方法、组合物和用途
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP2015532281A (ja) 2012-09-26 2015-11-09 マンカインド コーポレイション 複数キナーゼ経路阻害剤
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2018108167A1 (zh) * 2016-12-16 2018-06-21 基石药业 Cdk4/6抑制剂
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
US11174255B2 (en) 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
AU2019262579A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Salts of an FGFR inhibitor
US20220144819A1 (en) * 2018-11-20 2022-05-12 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
JP2022533182A (ja) * 2019-05-16 2022-07-21 ユニバーシティー オブ ヒューストン システム タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022005706A2 (pt) * 2019-10-01 2022-06-21 Goldfinch Bio Inc Inibidores de 1,6-naftiridina substituída de cdk5
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FR2706898B1 (es) * 1993-06-25 1995-09-08 Union Pharma Scient Appl
GEP20012444B (en) * 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Also Published As

Publication number Publication date
CA2291222C (en) 2004-03-30
DE69828408T2 (de) 2005-12-08
ATE286053T1 (de) 2005-01-15
BR9811956A (pt) 2000-08-15
US6150359A (en) 2000-11-21
JP2001515078A (ja) 2001-09-18
EP1003745B1 (en) 2004-12-29
DE69828408D1 (de) 2005-02-03
AU742999B2 (en) 2002-01-17
WO1999009030A1 (en) 1999-02-25
NZ502704A (en) 2002-06-28
AU8828998A (en) 1999-03-08
JP4965021B2 (ja) 2012-07-04
EP1003745A1 (en) 2000-05-31
ZA987491B (en) 1999-04-21
CA2291222A1 (en) 1999-02-25
KR20010023089A (ko) 2001-03-26
BR9811956B1 (pt) 2010-06-01

Similar Documents

Publication Publication Date Title
ES2235353T3 (es) Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
BR9709443B1 (pt) n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
DE69830404D1 (de) P38-inhibitoren
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
TR200002616T2 (tr) Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
EP1041982A4 (en) INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
MY117696A (en) INHIBITORS OF p38
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
PT937074E (pt) Benzonaftiridinas como terapeutica bronquica
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
ATE407947T1 (de) Proteine mit il-6 inhibitorischer wirkung
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
SE0202608D0 (sv) New sequences
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
GB9723824D0 (en) Cytostatic agents
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
ECSP992875A (es) Inhibidores de la proteina /tirosina/ cinasa /de imidazopiracina sustituidas con heterociclo